immuno-oncology

News

Opdivo backed by NICE for rare gastro-oesophageal cancers

Bristol-Myers Squibb's Opdivo has been recommended as a treatment for around 3,000 people with rare forms of gastro-oesophageal cancer via the NHS in England and Wales.

News

GSK's pullback from cell therapy continues as Immatics allia...

Immatics has become the latest partner for GSK in the area of cell therapy for cancer to see its alliance shelved, just two and a half years after being set up.

News

Normunity de-stealths, launches Series A immune normalisers

Biotech start-up Normunity, Inc.

News

J&J nabs FDA okay for BCMA bispecific Tecvayli

Johnson & Johnson has secured another regulatory approval for its BCMAxCD3 bispecific antibody for multiple myeloma – Tecvayli – adding to the wide range of therapies available for the

News

West Chester - Circa November 2020: AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

AstraZeneca gets first okay for CTLA4 drug tremelimumab

AstraZeneca's lengthy and turbulent development of CTLA4 inhibitor tremelimumab has at least led to a regulatory approval as part of a combination therapy for advanced liver cancer.

News

Atara closes on first approval of transplant complication th...

Atara Biotherapeutics' cell therapy Ebvallo should be approved to treat Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD), according to the EMA's human med

Opdivo backed by NICE for rare gastro-oesophageal cancers

GSK's pullback from cell therapy continues as Immatics allia...

Normunity de-stealths, launches Series A immune normalisers

J&J nabs FDA okay for BCMA bispecific Tecvayli

AstraZeneca gets first okay for CTLA4 drug tremelimumab

Atara closes on first approval of transplant complication th...

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

immuno-oncology

Editor's Picks